Phase I open label clinical trial of autologous T cell therapy for the treatment of cytomegalovirus (CMV) reactivation and disease after transplantation

QIMR Berghofer Medical Research Institute.0 个研究点目标入组 30 人开始时间: 2013年9月3日最近更新: 2023年3月20日

适应症

试验速览

暂无简介。

•1) Transplant recipients who were transplanted by, and/or are currently under the care of, a physician at the appropriate clinical facility.
•2). CMV infection that falls into one of the following categories:
•(2a) CMV reactivation (as defined by PCR) or disease (as defined by histology) following successful initial therapy, or
•(2b) Persistent CMV disease (no response to 2 weeks of salvage foscarnet or other second line antiviral agent), or
•(2c) Persistent CMV replication (more than 6 weeks by PCR) despite appropriate antiviral therapy, or
•(2d) Any CMV reactivation or disease where anti-viral therapy is contraindicated on the basis of intolerance or end organ limitation (e.g. renal impairment, marrow dysfunction).
•3) Absence of uncontrolled intercurrent infection
•4) Patient able to provide informed consent
•5) Aged 18 to 75

•1) Uncontrolled intercurrent infection
•2) ECOG status greater than 3 (Karnofsky performance score less than 30 : disabled, no self-care. Totally bedridden, or confined to chair)
•3) Markers of active HBV, HCV, HIV, HTLV I and II and syphilis infection (presence of HbsAg, HepC antibody, HIV antibody, antibodies to HTLV I and II and positive serological test for syphilis, or positive nucleic acid test (NAT) for HIV, HBV or HCV)
•4) Uncontrolled graft rejection.
•5) Steroid doses greater than 1mg/kg/day of prednisone, or equivalent
•6) Insufficient T cells for in vitro expansion
•7) Women who are lactating, pregnant, or unwilling to use adequate contraception

发起方